FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website www.fitscreening.eu/patients

 

 

Please select your country. This will keep you up to date with your country-specific information.

Precisely brings to light what you need to see

OncoBEAM liquid biopsy for mutation detection

Precision diagnostics are key to selecting the right therapy at the right time for the right cancer patient. Therefore, reliable assessment of the tumour’s mutational status is decisive in selecting cancer patients eligible for targeted therapy. Although it is the standard in clinical oncology, analysing mutations in tumour tissue comes with considerable drawbacks. Biopsies can significantly increase the cost of patient care, are inconvenient from a scheduling perspective and are not without clinical complications.1 Moreover, they are subject to selection bias due to tumour heterogeneity, can be difficult to obtain in sufficient amounts and the information provided is restricted to a static time point.2,3 Here, liquid biopsy based on the analysis of mutations in cell-free tumour DNA (ctDNA) has become a valuable tool for a variety of clinical and investigative applications. The detection of clinically relevant mutations from a simple blood draw enables you to select the most beneficial therapy and monitor the patient’s response to therapy in real-time without the need for physical biopsies.

The Sysmex way of liquid biopsy: Sysmex Inostics OncoBEAM

Sysmex Inostics has been the pioneer in liquid biopsy by implementing OncoBEAM into the clinical routine. OncoBEAM combines digital droplet PCR with flow cytometry and provides highly sensitive mutation detection based on ctDNA isolated from blood samples. Thereby it offers new possibilities for cancer management & clinical research.

The OncoBEAM Advantage

  • Reliable detection of mutations from cell-free DNA that occur at mutant allele frequencies (MAF) as low as 0.01%
  • Viable alternative to tissue testing due to its high concordance (>90%) with tissue biopsy
  • Timely and minimally-invasive analysis of specific mutations before or during targeted therapy

References

  1. Overman MJ, Modak J, Kopetz S, et al: Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J Clin Oncol 31:17-22, 2013
  2. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 339:1546-1558, 2013
  3. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012

 

 

Oncology

"OncoBEAM supports all oncologists in making critical patient-related decisions."

Prof. Jesús García-Foncillas MD PhD, University Hospital Fundación Jiménez Díaz, Spain

Read interview

Confident your mCRC patient is eligible for anti-EGFR therapy?

OncoBEAM Technology

Watch video
Watch video
Watch Carmen’s story